Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Although tumor necrosis factor inhibitors (TNFis) have improved management of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); many patients experience suboptimal disease control. We quantified achievement of varying degrees of disease activity in patients with PsA and axSpA who initiated and maintained TNFi treatment for 12 months.
Methods
Patients with PsA or axSpA enrolled in the PPD™ CorEvitas™ PsA/Spondyloarthritis Registry were included in the study. Varying degrees of disease control were quantified based on minimal disease activity (MDA) status for PsA and BASDAI50 (≥ 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index) status for axSpA at 6 and 12 months. Patients were categorized into four groups: sustained (MDA/BASDAI50 at 6 and 12 months), improved (MDA/BASDAI50 at 12 months only), worsened (MDA/BASDAI50 at 6 months only), and never achieved (no MDA/BASDAI50 at 6 or 12 months).
Results
For PsA, 338 patients initiated and persisted on TNFis. At 6 months, the majority (65%, n = 221) did not achieve MDA status; of these, 86% (n = 189) still did not achieve MDA at 12 months. For axSpA, 152 patients initiated and persisted on TNFis. At 6 months, 80% (n = 121) did not achieve BASDAI50; among these patients, 91% (n = 110) still did not achieve BASDAI50 status at 12 months. For both PsA and axSpA initiators, the risk of not achieving clinical or quality of life outcomes was two- to threefold lower in patients who never achieved versus patients who achieved and sustained MDA/BASDAI50.
Conclusion
More than 80% of patients with PsA or axSpA who did not achieve low disease activity at 6 months still did not achieve low disease activity by 12 months even though they persisted on TNFi treatment. These findings underscore the importance for physicians to consider modifying therapy if treatment targets with TNFi have not been achieved in the first 6 months.
Prior Presentation: EULAR 2024 (PsA presented as poster, axSpA published as abstract). Mease P, Ye X, Saffore CD, Parikh B, Blachley T, Eliot M, Middaugh N, Ogdie A. “Real-world Burden of Uncontrolled Disease Despite Treatment with Tumor Necrosis Factor Inhibitors Among Psoriatic Arthritis Patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.” Poster presented at: European Congress of Rheumatology (EULAR), 12–15 June 2024, Vienna Austria. Ogdie A, Ye X, Saffore CD, Parikh B, Blachley T, Eliot M, Middaugh N, Mease P. Real-world Burden of Uncontrolled Disease Despite Treatment with Tumor Necrosis Factor Inhibitors among Axial Spondyloarthritis Patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [EULAR abstract] Ann Rheum Dis. 2024;83(Suppl 1):1735. https://doi.org/10.1136/annrheumdis-2024-eular.914.
Key Summary Points
Why carry out this study?
Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are chronic immune-mediated inflammatory diseases that can result in functional disability and reduced quality of life
Despite tumor necrosis factor inhibitor (TNFi) therapy substantially improving management of PsA and axSpA, many patients with these diseases are either not able to achieve or not able to maintain optimal disease control
To better understand and improve treatment management of these chronic inflammatory diseases, this study assessed the achievement of low disease activity in a clinical practice setting in patients with PsA or axSpA who initiated and maintained a TNFi but did not achieve low disease activity after two consecutive follow-up visits over 12 months, compared with patients who successfully achieved low disease activity
What was learned from the study?
Despite initiating and maintaining TNFi therapy, approximately 70%–80% of patients with PsA and axSpA never achieved low disease activity at 6 months and almost 90% of these patients did not achieve low disease activity at 12 months.
Patients with PsA or axSpA who do not respond to TNFi therapy at 6 months are unlikely to respond in the longer term if maintained on TNFi therapy
These findings highlight an unmet need for more effective treatment strategies to manage these complex, chronic inflammatory diseases as well as a need for healthcare providers to consider changes in therapy if treatment goals have not been met by 6 months
Introduction
Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease that includes musculoskeletal (peripheral arthritis, enthesitis, dactylitis, and spondylitis) and dermatologic (skin and nail psoriasis) manifestations [1, 2]. Axial spondyloarthritis (axSpA) is also a chronic, inflammatory musculoskeletal disease that affects the axial skeleton (spine and sacroiliac joints) or peripheral joints and entheses [3, 4]. Both PsA and axSpA are progressive diseases that can result in structural damage, permanent disability, impaired work productivity, psychosocial impairment, and a substantial deterioration in quality of life (QoL) [5‐13].
Anzeige
Phase 3 clinical trials have demonstrated that treatment of these immune-mediated inflammatory diseases with TNF inhibitors (TNFis), compared with placebo, not only reduces disease activity but also results in a decrease in joint pain, swelling, and tenderness; and slows the progression of joint damage [14‐20]. As a result, TNFis are commonly used as first-line biologic therapy in the treatment of PsA and axSpA [21‐25]. However, despite the effectiveness of TNFis in reducing inflammation and disease activity, and improving the symptoms and physical function in some patients suffering from PsA and axSpA, approximately 68% of patients with PsA [26] and approximately 67% of those with axSpA [27] are unable to reach optimal disease control. At present, optimal disease control is considered to be the attainment of the treatment targets of remission or low disease activity [21‐25]. This study aimed to quantify the proportion of patients with PsA and axSpA who never achieved low disease activity compared with those who achieved varying degrees of disease activity, including those who successfully achieved low disease activity among patients who initiated and maintained TNFi treatment for 12 months in a clinical practice setting.
Methods
Data Source
The PPD™ CorEvitas™ PsA/SpA Registry, which began enrolling patients in the USA in 2013, is a prospective multicenter, non-interventional registry for adult patients with PsA or SpA being treated by a rheumatologist. Demographics, disease duration, medical history (including current and prior treatments for PsA or SpA), smoking status, alcohol use, disease activity and severity, clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes are collected from patients and their rheumatologists during routine clinical visits using registry questionnaires. Blood collection and other diagnostic tests were not required for participation; however, relevant standard of care laboratory and imaging results were reported if available.
As of August 2023, the CorEvitas PsA/SpA Registry included patients from 68 private and academic clinical sites with 78 physicians throughout 30 states in the USA. The registry enrolled 6276 patients with PsA/SpA. The mean and median follow-up time for patients was 3.6 years and 2.9 years, respectively.
Patients were eligible to enroll in the Registry if they were ≥ 18 years old, able to provide written informed consent, and met one of the following criteria: (1) diagnosed with PsA and initiated (prescribed or started) an approved medication for the treatment of PsA at the time of enrollment; (2) met the Assessment of SpondyloArthritis international Society (ASAS) criteria for axSpA, including radiographic or non-radiographic criteria, and initiated (prescribed or started) an approved medication for the treatment of axSpA at the time of enrollment; (3) met the modified New York classification criteria for ankylosing spondylitis and initiated (prescribed or started) an approved medication for the treatment of ankylosing spondylitis at the time of enrollment. Patients were excluded from enrollment in the CorEvitas PsA/SpA Registry if they had a diagnosis of rheumatoid arthritis, systemic lupus erythematosus, or any other form of autoimmune inflammatory arthritis; or were participating in or planned to participate in a clinical trial of an interventional research study of a non-marketed or marketed investigational drug (e.g. phase 1–4 clinical drug trial, post-marketing study, or registry study where drug was being provided).
Anzeige
This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting non-interventional research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), namely, the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to the PPD™ clinical research business of Thermo Fisher Scientific (Waltham, MA, USA) before the site’s participation and initiation of any study procedures. All patients enrolled in the PPD™ CorEvitas™ PsA/SpA Registry were required to provide written informed consent and authorization before participating in the study.
PsA Study Population Criteria
The PsA observational cohort for this analysis included patients with PsA enrolled in the CorEvitas PsA/SpA Registry, who initiated (from April 2013–August 2022) and persisted on the same TNFi of any line of therapy at or after the enrollment visit. Patients could not switch to another TNFi to be included in this study. Patients had to have a clinical diagnosis of PsA made by the treating rheumatologist, not be in minimal disease activity (MDA)[28] at baseline, and have valid baseline, 6 (± 3)-month, and 12 (± 3)-month follow-up visits. MDA was defined as meeting at least five of the seven MDA components: body surface area (BSA) ≤ 3%, Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ 0.5, tender joint count (TJC) ≤ 1, swollen joint count (SJC) ≤ 1, patient pain on visual analog scale (VAS 0–100) ≤ 15, patient global assessment of arthritis (VAS 0–100) ≤ 20; and Spondyloarthritis Research Consortium of Canada Enthesitis Index ≤ 1.
For data analysis, patients with PsA were stratified into one of four subgroups (sustained, improved, worsened, or never achieved status, respectively) according to their MDA status at the 6- and 12-month follow-up visits (Table 1).
Table 1
Cohort definitions for psoriatic arthritis (MDA status) and axial spondyloarthritis (BASDAI50 status)
MDA or BASDAI50 status group
MDA or BASDAI50 status at 6-month follow-up visit
MDA or BASDAI50 status at 12-month follow-up visit
Sustained
Yes
Yes
Improved
No
Yes
Worsened
Yes
No
Never achieved
No
No
BASDAI50 50% improvement from the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score, MDA minimal disease activity
Clinical and QoL Outcomes in Patients with PsA
Clinical features, stratified by MDA status, were assessed at the 6- and 12-month follow-up visits for each of the four subgroups (sustained, improved, worsened, or never achieved status, respectively) and included Clinical Disease Activity in Psoriatic Arthritis low disease activity (cDAPSA LDA) composite score [29, 30], enthesitis and dactylitis counts, and BSA ≤ 3%. The composite disease activity score, cDAPSA, was calculated as the sum of TJC, SJC, patient pain assessment, and patient global assessment of arthritis activity. Higher cDAPSA scores indicate more severe disease activity, and cDAPSA LDA was defined as a score ≤ 13.
Patient-reported outcomes (PROs) were also evaluated at the 6- and 12-month follow-up visits for the four subgroups of patients with PsA. These outcomes included the HAQ-DI, which is used to assess the impact of PsA on physical function [31] and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), which is a broad composite score consisting of six questions that assess the severity of fatigue, spinal and peripheral joint pain, localized tenderness, and morning stiffness [32, 33]. The BASDAI score has a range of 0 to 10 with scores ≥ 4 considered to indicate high disease activity [34]. PROs included individual VAS (0–100) scores for patient pain, patient fatigue, and severity of morning stiffness. Overall work impairment was derived from the work time missed and impairment while working domains of the Work Productivity and Activity Impairment (WPAI) questionnaire [35].
axSpA Study Population Criteria
The axSpA observational cohort for this analysis included patients with axSpA enrolled in the CorEvitas PsA/SpA Registry who initiated (from August 2013–August 2022) and persisted for 12 months on the same TNFi of any line of therapy, at or after the enrollment visit. Patients could not switch to another TNFi to be included in this study. Patients had to have a clinical diagnosis of axSpA as determined by the treating rheumatologist and have valid baseline and 6 (± 3)- and 12 (± 3)-month follow-up visits. BASDAI was used to determine patient-reported disease activity in patients with axSpA. BASDAI50 was defined as a ≥ 50% improvement from the original BASDAI score at baseline.
For analysis of data, patients with axSpA were stratified into one of four subgroups (sustained, improved, worsened, or never achieved status, respectively) according to their BASDAI50 status at the 6- and 12-month follow-up visits (Table 1).
Clinical and QoL Outcomes in Patients with axSpA
Clinical features of axSpA, stratified by BASDAI50 status, were assessed at the 6- and 12-month follow-up visits for each of the four subgroups (sustained, improved, worsened, or never achieved status, respectively), and included the composite measures of Ankylosing Spondylitis Disease Activity Score (ASDAS), LDA, and ASAS40. The ASDAS consists of five questions about back pain, peripheral pain/swelling, duration of morning stiffness, patient global assessment of arthritis, and C-reactive protein; the ASDAS LDA is defined as an ASDAS score < 2.1 [32, 36]. The ASAS40 response is defined as a ≥ 40% improvement and an absolute improvement from baseline of ≥ 2 units (range 0–10) in ≥ 3 of the four components (patient’s global assessment of disease activity, spinal pain, physical function as measured by Bath Ankylosing Spondylitis Functional Index [BASFI], and stiffness) without any worsening in the remaining component [37]. PROs were also evaluated at the 6- and 12-month follow-up visits for the four subgroups of patients with axSpA stratified by BASDAI50 status. Outcomes included the ASAS Health Index (ASAS HI), BASDAI, and BASFI. ASAS HI contains 17 items that address a broad range of functioning, disability, and health relevant to axSpA [38], and scores range from 0 to 17, with lower scores indicating better overall health status. BASFI consists of eight questions regarding function and two questions assessing a patient’s ability to cope with everyday life [39], and scores range from 0 to 10, with higher scores indicating greater functional disability. Additional PROs included individual VAS (0–100) scores for patient pain, patient fatigue, and morning stiffness severity. Overall work impairment was derived from the work time missed and impairment while working domains of the WPAI Impairment questionnaire [35].
Anzeige
Data Analysis in PsA and axSpA Cohorts
Baseline patient characteristics were summarized as the mean and standard deviation (SD) or as frequencies and percentages. The baseline visit was defined either as the visit coinciding with the reported TNFi initiation date or—if the initiation was between visits—as the visit immediately prior to the report of initiation if that visit occurred ≤ 4 months prior to the reported treatment initiation. If the visit at which initiation was reported > 1 month after initiation, the patient was excluded from the analysis for lack of treatment index data. For patients in the sustained and never achieved subgroups, the frequency and proportion of patients achieving functional, clinical, and QoL outcomes were reported at the 6- and 12-month follow-up visits. Rates of achievement were calculated among patients who were not in the outcome state at baseline.
Poisson regression models, adjusting for age, race, sex, work status, time since PsA or axSpA diagnosis, and line of therapy (0, 1, 2+ prior biologic/targeted synthetic disease-modifying antirheumatic drug [DMARD] therapies) were used to estimate the association between disease status group (sustained vs never achieved status) and achievement of clinical outcomes as well as those who met or exceeded a minimum clinically important difference (MCID) in PROs at the 6- and 12-month follow-ups; covariate-adjusted relative risk ratios (95% confidence intervals [CIs]) were reported at both follow-up visits. MCIDs for PROs are summarized in Table 2.
Table 2
Minimum clinically important differences for patient-reported outcomes
Patient-reported outcomes
Minimum clinically important difference
HAQ-DI (0–3)
≥ 0.35-point decrease
BASDAI VAS (0–10)
≥ 1.1-point decrease
BASFI VAS (0–10)
≥ 0.6-point decrease
ASAS-HI VAS (0–17)
≥ 3.0-point decrease
Patient pain (VAS 0–100)
≥ 10.0-point decrease
Patient fatigue (VAS 0–100)
≥ 10.0-point decrease
Morning stiffness severity (VAS 0–100)
≥ 10.0-point decrease
Overall work impairment (0–100%)
≥ 15.0-point decrease
ASAS-HI Assessment of Spondyloarthritis international Society Health Index, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HAQ-DI Health Assessment Questionnaire Disability Index, VAS visual analogue scale
Results
PsA—Baseline Characteristics by MDA Status
Of the 338 patients with PsA who initiated and persisted on TNFis, 35% (117/338) achieved MDA and 65% (221/338) did not achieve MDA at 6 months (Fig. 1). Of the patients who achieved MDA at 6 months, 76% (89/117) sustained MDA at 12 months and 24% (28/117) worsened. Of those who did not achieve MDA at 6 months, 14% (32/221) improved and 86% (189/221) never achieved MDA at 12 months.
Fig. 1
PsA cohort selection and MDA achievement in patients with PsA who initiated and maintained TNFis through 12 months of follow-up. Numbers may not add up to 100% due to rounding. MDA minimal disease activity, PsA psoriatic arthritis, TNFi tumor necrosis factor inhibitor
The proportion of female patients was higher in the never achieved subgroup compared with the sustained subgroup (66.0% vs 55.7%; Table 3). At baseline, PsA disease duration was greater in the never achieved MDA subgroup compared with the sustained MDA subgroup (6.3 vs 4.3 years). PsA disease activity measures and PRO symptomology varied across the MDA status groups. At least 50% of patients in all MDA status subgroups were TNFi-treatment-naïve at baseline.
Table 3
Baseline characteristics in patients with psoriatic arthritis stratified by minimal disease activity status
Baseline characteristics
PsA subgroups according to MDA status
Sustained, N = 89
Improved, N = 32
Worsened, N = 28
Never achieved, N = 189
Demographics
Age (years), mean ± SD
48.9 ± 14.9
52.9 ± 11.8
55.5 ± 10.1
57.3 ± 12.1
Female patients, n (%)
49 (55.7)
15 (46.9)
17 (60.7)
124 (66.0)
Race, white, n (%)
79 (91.9)
29 (93.5)
21 (77.8)
170 (92.4)
PsA disease characteristics, mean ± SD
Years since PsA diagnosis
4.3 ± 6.0
4.4 ± 5.8
6.0 ± 7.6
6.3 ± 7.4
Years since PsA symptom onset
6.7 ± 8.4
6.9 ± 7.2
7.3 ± 6.7
10.5 ± 9.7
PsA disease activity measures
SJC, mean ± SD
5.4 ± 6.0
3.8 ± 5.7
3.1 ± 2.9
4.6 ± 6.8
TJC, mean ± SD
7.2 ± 7.8
4.0 ± 5.5
8.4 ± 9.5
9.2 ± 10.6
cDAPSA score, mean ± SD
21.6 ± 14.3
17.1 ± 11.7
21.4 ± 11.8
25.9 ± 16.9
Presence of dactylitis, n (%)
37 (41.6)
4 (12.5)
5 (17.9)
28 (14.8)
Presence of enthesitis, n (%)
24 (27.0)
4 (12.5)
6 (21.4)
70 (37.0)
BASDAI VAS (0–10), mean ± SD
4.6 ± 2.2
4.2 ± 2.1
5.0 ± 1.9
6.1 ± 1.9
BSA > 3%, n (%)
28 (31.8)
14 (45.2)
8 (28.6)
58 (31.9)
PROs, mean ± SD
Patient global assessment of arthritis VAS (0–100)
38.5 ± 24.2
41.2 ± 23.6
49.9 ± 17.8
54.8 ± 21.9
Patient global assessment of arthritis and psoriasis VAS (0–100)
39.7 ± 24.7
43.7 ± 22.9
47.2 ± 22.3
54.3 ± 21.2
HAQ-DI (0–3)
0.7 ± 0.5
0.7 ± 0.6
1.0 ± 0.6
1.2 ± 0.6
Patient pain VAS (0–100)
49.7 ± 26.5
47.7 ± 22.4
47.1 ± 25.0
64.3 ± 20.6
Patient fatigue VAS (0–100)
43.7 ± 28.5
45.9 ± 28.6
48.2 ± 23.1
62.2 ± 23.0
Patient spine pain VAS (0–100)
21.7 ± 24.7
30.7 ± 26.9
35.0 ± 27.6
49.6 ± 29.4
Morning stiffness VAS (0–100)
51.8 ± 29.8
42.5 ± 24.6
49.3 ± 23.1
64.4 ± 23.9
WPAI (0–100%), mean ± SD
Work time missed
5.7 ± 14.8
8.9 ± 24.1
25.8 ± 34.1
9.9 ± 23.5
Impairment while working
24.8 ± 22.9
20.4 ± 18.5
36.6 ± 24.6
39.2 ± 24.5
Overall work impairment
29.6 ± 25.2
21.9 ± 21.3
52.2 ± 31.7
44.7 ± 26.8
Activity impairment
35.7 ± 28.1
35.1 ± 30.0
38.1 ± 25.4
53.5 ± 24.5
Number of prior TNFis, n (%)a
0
58 (66.7)
18 (58.1)
17 (60.7)
88 (50.3)
1
20 (23.0)
11 (35.5)
8 (28.6)
58 (33.1)
≥ 2
9 (10.3)
2 (6.5)
3 (10.7)
29 (16.6)
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BSA body surface area, cDAPSA Clinical Disease Activity in Psoriatic Arthritis, HAQ-DI Health Assessment Questionnaire-Disability Index, MDA minimal disease activity, PROs patient-reported outcomes, PsA psoriatic arthritis, SD standard deviation, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, VAS visual analogue scale, WPAI Work Productivity and Activity Impairment Questionnaire
aDenominators included only those patients who had data for this variable
Anzeige
PsA—Achievement of Clinical and QoL Outcomes by MDA Status
Patients who never achieved MDA experienced higher disease activity compared with patients with sustained MDA at both 6 and 12 months (Fig. 2). Lower proportions of patients who never achieved MDA reported improvements in PROs that exceeded the MCID compared to patients with sustained MDA at both 6 and 12 months (Fig. 2). Based on the results from adjusted regression models, patients who never achieved MDA had a two- to threefold higher risk of not achieving disease activity measures and MCIDs in PROs compared with those who achieved sustained MDA over 12 months.
Fig. 2
a, b Proportion of patients in the sustained versus never achieved subgroups who achieved the PsA disease activity measures of cDAPSA LDA, enthesitis count = 0, dactylitis count = 0, TJC = 0, SJC = 0, and BSA ≤ 3% at 6 months (a) and 12 months (b). c, d Proportion of patients in the sustained versus never achieved subgroups who achieved MCIDs in the PROs HAQ-DI ≥ 0.35-point decrease, BASDAI ≥ 1.1-point decrease, patient pain ≥ 10.0-point decrease, patient fatigue ≥ 10.0-point decrease, morning stiffness severity ≥ 10.0-point decrease, and overall work impairment ≥ 15.0-point decrease at 6 months (c) and 12 months (d). The adjusted models estimate the relative risk of sustained MDA vs never achieved MDA as the reference. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BSA body surface area, cDAPSA LDA Clinical Disease Activity Index for Psoriatic Arthritis Low Disease Activity, CI confidence interval, HAQ-DI Health Assessment Questionnaire Disability Index, MCID minimum clinically important difference, MDA minimal disease activity, PRO patient-reported outcome, PsA psoriatic arthritis, RR risk ratio, SJC swollen joint count, TJC tender joint count
Of the 152 patients with axSpA who initiated and persisted on TNFis, 20% (31/152) achieved BASDAI50 and 80% (121/152) did not achieve BASDAI50 at 6 months (Fig. 3). Of those who achieved BASDAI50 at 6 months, 61% (19/31) sustained BASDAI50 at 12 months. Of those who did not achieve BASDAI50 at 6 months, 91% (110/121) never achieved disease control at 12 months despite persistent TNFi treatment. At baseline, lower disease activity and PRO symptomology were reported among the subgroup that sustained BASDAI50 compared with the subgroup that never achieved BASDAI50 (Table 4). Across the BASDAI50 status groups, 55% of patients were TNFi treatment-naïve at baseline.
Fig. 3
axSpA cohort selection and BASDAI50 achievement in patients with axSpA who initiated and maintained TNFis through 12 months of follow-up. BASDAI50 was defined as 50% improvement in the BASDAI. axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, TNFi tumor necrosis factor inhibitor
Baseline characteristics in patients with axial spondyloarthritis stratified by 50% improvement from the original Bath Ankylosing Spondylitis Disease Activity Index status
Baseline characteristics
AxSpa subgroups according to BASDAI50 status
Sustained, N = 19
Improved, N = 11
Worsened, N = 12
Never achieved, N = 110
Demographics
Age (years), mean ± SD
45.6 ± 15.1
48.5 ± 13.9
47.2 ± 14.2
53.0 ± 13.7
Female patients, n (%)
7 (36.8)
7 (63.6)
4 (33.3)
60 (55.0)
Race, white, n (%)
14 (73.7)
10 (90.9)
10 (83.3)
100 (91.7)
axSpA disease characteristics, mean ± SD
Years since axSpA diagnosis
7.4 ± 10.3
6.4 ± 7.3
7.6 ± 11.3
7.1 ± 10.1
Years since axSpA symptom onset
13.0 ± 10.7
12.9 ± 9.2
12.0 ± 10.7
16.0 ± 12.0
axSpA disease activity measures
SJC, mean ± SD
0.5 ± 1.3
0.7 ± 1.6
0.5 ± 1.2
1.5 ± 3.0
TJC, mean ± SD
1.1 ± 2.2
2.7 ± 4.0
2.0 ± 5.2
4.4 ± 11.4
Presence of dactylitis, n (%)
1 (5.3)
1 (9.1)
0 (0.0)
6 (5.5)
Presence of enthesitis, n (%)
6 (31.6)
2 (18.2)
3 (25.0)
35 (31.8)
ASDAS, mean ± SD
2.9 ± 0.9
2.5 ± 1.0
2.7 ± 0.7
2.8 ± 1.2
HLA-B27 positive, n (%)
9 (47.4)
4 (36.4)
7 (58.3)
40 (36.4)
Elevated CRP, n (%)
6 (31.6)
4 (36.4)
0 (0.0)
25 (22.7)
PROs, mean ± SD
Patient global assessment of arthritis VAS (0–100)
48.5 ± 2.1
75.2 ± 30.6
61.0 ± 19.1
55.8 ± 24.5
ASAS-HI VAS (0–17)
4.1 ± 2.9
7.4 ± 3.5
5.5 ± 2.1
8.2 ± 4.0
BASFI VAS (0–10)
2.6 ± 2.3
2.8 ± 1.5
3.6 ± 1.6
4.1 ± 2.8
HAQ-DI (0–3)
0.8 ± 0.6
0.6 ± 0.3
0.6 ± 0.3
0.9 ± 0.7
Patient pain VAS (0–100)
49.6 ± 32.2
46.0 ± 25.4
64.3 ± 19.3
53.0 ± 27.0
Patient fatigue VAS (0–100)
44.4 ± 33.7
42.8 ± 31.5
58.2 ± 22.9
52.0 ± 30.4
Patient spine pain at night VAS (0–100)
41.1 ± 32.4
46.4 ± 28.0
56.3 ± 31.9
46.3 ± 30.6
Morning stiffness VAS (0–100)
60.4 ± 32.1
47.5 ± 28.3
64.3 ± 27.5
51.7 ± 30.1
WPAI questionnaire (0–100%), mean ± SD
Work time missed
5.2 ± 13.8
6.4 ± 11.1
6.5 ± 16.6
9.2 ± 23.0
Impairment while working
31.6 ± 26.2
33.8 ± 29.5
34.2 ± 26.3
34.8 ± 31.8
Overall work impairment
35.3 ± 28.2
37.2 ± 32.7
36.9 ± 22.2
37.8 ± 32.6
Activity impairment
34.4 ± 29.6
29.0 ± 15.5
47.6 ± 20.6
48.0 ± 30.7
Number of prior TNFis, n (%)a
0
10 (58.8)
6 (54.5)
8 (72.7)
54 (52.4)
1
4 (23.5)
5 (45.5)
2 (18.2)
37 (35.9)
≥ 2
3 (17.6)
0 (0.0)
1 (9.1)
12 (11.7)
ASAS-HI Assessment of Spondyloarthritis international Society Health Index, ASDAS Ankylosing Spondylitis Disease Activity score, axSpA axial spondyloarthritis, BASDI Bath Ankylosing Spondylitis Disease Activity Index, BASDAI50 50% improvement from the original BASDAI score at baseline, BASFI Bath Ankylosing Spondylitis Functional Index, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, HLA-B27 human leukocyte antigen B27, PROs patient-reported outcomes, PsA psoriatic arthritis, SD standard deviation, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, VAS visual analogue scale, WPAI Work Productivity and Activity Impairment
aDenominators included only those patients who had data for this variable
axSpA—Achievement of Clinical and QoL Outcomes by BASDAI50 Status
Patients who never achieved BASDAI50 experienced higher disease activity and worse PROs at 6 and 12 months versus those with sustained BASDAI50 (e.g., ASDAS LDA at 6 months was 14% vs 88%, and at 12 months was 9% vs 100%, respectively; Fig. 4). The adjusted regression models demonstrated that patients who never achieved BASDAI50 had at least a twofold higher risk of not achieving disease activity measures and MCIDs in PROs compared with those who achieved sustained BASDAI50. Similar improvements were observed in ASAS40 and ASAS HI for those patients with sustained BASDAI50 at 6 and 12 months (Electronic Supplementary Material Fig. S1); however, these data should be interpreted with caution due to the limited sample size.
Fig. 4
a, b Proportion of patients in the sustained versus never achieved subgroups who achieved the axSpA disease activity measures of ASDAS LDA, BASFI ≥ 0.6-point decrease, and BASDAI ≥ 1.1-point decrease at 6 months (a) and 12 months (b). c, d Proportion of patients in the sustained versus never achieved subgroups who achieved MCIDs in the PROs of patient pain ≥ 10.0-point decrease, patient fatigue ≥ 10.0-point decrease, morning stiffness severity ≥ 10.0-point decrease, and overall work impairment ≥ 15.0-point decrease at 6 months (c) and 12 months (d). The adjusted models estimate the relative risk of sustained BASDAI50 vs never achieved BASDAI50 as the reference. ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, CI confidence interval, LDA low disease activity, MCID minimum clinically important difference, PRO patient-reported outcome, RR risk ratio
Psoriatic arthritis and axSpA are both chronic inflammatory diseases that significantly impact QoL and functional abilities [5, 10‐12, 22, 40, 41]. Despite the success of TNFis in the management of these diseases, many patients with PsA and axSpA experience suboptimal disease control [26, 27]. Patients unable to achieve good disease control within 6 months are at increased risk of further joint damage and also may be at increased risk for extra-musculoskeletal manifestations such as psoriasis, uveitis, and inflammatory bowel disease, as well as cardiovascular disease, metabolic syndrome, liver disease, depression, and anxiety [42‐48]. Patients with higher levels of disease activity also have greater healthcare resource utilization and higher medical costs [49]. All of this highlights the need for healthcare providers to reconsider the management of patients who do not achieve treatment goals.
Anzeige
In the PsABio real-world, international observational cohort study, approximately 32% of TNFi-treated patients with PsA achieved the treatment goal of MDA at 6 months [26]. These results are comparable to those observed in our study in the USA in which approximately 35% of patients with PsA who were treated with TNFi achieved MDA at 6 months. For axSpA, data from the EuroSpA research collaboration showed that 27% of patients treated with TNFi in clinical practice achieved ASDAS inactive disease at 6 months [27]. In our study, where disease activity was assessed by BASDAI, 20% of patients achieved BASDAI50 at 6 months. Thus, less than half of the patients with axSpA in the European studies and in this study in the USA who were treated with TNFi achieved their treatment target of low disease activity at 6 months.
In our study in patients with PsA, we found that approximately seven out of ten patients who initiated a TNFi and persisted on therapy never achieved MDA at 6 months, with almost 90% of these patients still not achieving MDA at 12 months. In patients with axSpA, approximately eight out of ten patients who initiated a TNFi and persisted on therapy never achieved BASDAI50 at 6 months and 90% never achieved BASDAI50 at 12 months. Patients with PsA or axSpA who did not respond to treatment at 6 months were not likely to respond in the longer term if maintained on TNFi therapy. For both PsA and axSpA, patients who never achieved MDA and BASDAI50, respectively, reported higher disease activity at 6 and 12 months, characterized by worse clinical outcomes and PROs, highlighting the importance of achieving low disease activity early and identifying and managing risk factors for non-response to therapy such as obesity.
Our findings indicate that patients with PsA or axSpA should be closely monitored for failure to achieve clinically meaningful improvements in disease activity at approximately 6 months following initiation of their treatment regimen. Assessment of these patients should include all domains of the disease (i.e., axial disease, peripheral arthritis, enthesitis, dactylitis, psoriatic nail disease, skin psoriasis, inflammatory bowel disease, and uveitis) [22, 23]. Consideration should also be given to the level of pain experienced by the patient, the impact of the disease on QoL, physical function, and structural damage, as well as comorbidities and related conditions and the patient’s own treatment goals [22, 23, 50].
Comorbidities, such as fibromyalgia and depression/anxiety, can greatly impact clinical disease activity indices in patients with PsA [51, 52]. Patients who have both PsA and fibromyalgia have been reported to have worse QoL and greater functional impairment compared with those with PsA only [52]. Patients who have both PsA and fibromyalgia are less likely to achieve MDA (risk ratio = 0.57, 95% CI 0.45–0.71; p < 0.0001) [51]. While the Registry captures fibromyalgia and other comorbid conditions, this study’s sample size limited our ability to adjust for all factors, potentially leading to a small degree of residual confounding.
It is important to keep in mind additional limitations of this study when interpreting the results. Given this is a non-interventional registry, patients are not randomly assigned to an intervention and patient follow-up in a registry is not encouraged as it is in clinical trials. However, compared to clinical trials, the patient population included in a registry is broader, with a larger range of comorbidities, demographic characteristics, disease severity, and is more generalizable to the population of patients with PsA and axSpA. There are potential biases, such as selection bias in registry data based on how patients are enrolled, and how data are collected over time. Physicians and patients volunteer to participate in the Registry; therefore, the population may not be representative of the general population of patients with PsA and axSpA. Patients were required to have three consecutive visits from the initiation of a TNFi through 12 months of follow-up. Fulfilling this requirement may have excluded patients who missed one or two visits—patients who are doing well may tend to skip interim visits—so this study may have underestimated the effects and limited the generalizability of the results to the population of patients with PsA and axSpA who persist on therapy for 12 months. Missing or incomplete data may also represent a potential bias; however, the CorEvitas PsA/SpA Registry has minimal missing data values (< 5%) in disease demographic, lifestyle and disease activity, and PRO variables among patients with follow-up visits. Although the objective of this study was to quantify the proportion of patients with PsA and axSpA by varying degrees of disease activity achievement compared with those who sustained low disease activity control among patients who initiated and sustained TNFi treatment for 12 months in a clinical practice setting, the improved and worsened groups were not discussed in more detail because the sample size in these subgroups does not allow for strong conclusions or interpretation of results; therefore, we kept our focus on the sustained and never achieved groups for interpretation and conclusions. Furthermore, the small sample size of the axSpA group impacted the power of this study to detect statistically significant differences, likely impacted the interpretation of the outcomes, and limited the generalizability of the findings.
Conclusions
In summary, a majority of patients with PsA and axSpA did not achieve treatment targets despite sustained TNFi therapy, underscoring an unmet need for more effective treatment strategies or personalized medicine approaches to manage these complex, chronic inflammatory diseases. Patients with PsA or axSpA who did not respond to treatment at 6 months were not likely to respond in the longer term if maintained on TNFi therapy. Both PsA and axSpA patients who never achieved treatment goals reported a greater disease activity at 6 and 12 months, characterized by worse clinical and patient-reported outcomes, highlighting the importance of achieving low disease activity and the need for healthcare providers to consider changes in therapy before 12 months if treatment goals have not been met by 6 months.
Medical Writing/Editorial Assistance
Medical writing support was provided by Joann Hettasch, PhD, of Avalere Health, LLC., and was funded by AbbVie.
Declarations
Conflict of Interest
Philip Mease has received research support, consulting fees, and/or speaker bureau support from AbbVie, Acelyrin, Amgen, BMS, Century, Cullinan, Lilly, Inmagene, Johnson & Johnson, Moonlake Pharma, Novartis, Pfizer, Spyre, Sun, UCB, and Takeda. Xiaolan Ye, Christopher D Saffore, Bhumik Parikh, and Sandra Ciecinski are employees of AbbVie and may own stock or stock options. Taylor Blachley is an employee and stockholder of Thermo Fisher Scientific, Inc. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Melissa Eliot and Nicole Middaugh are employees of Thermo Fisher. CorEvitas Clinical Registries are supported through contracted subscriptions with multiple pharmaceutical companies. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Alexis Ogdie is a consultant for AbbVie, Amgen, BMS, Celgene, the PPD clinical research business of Thermo Fisher, Gilead, GSK, Janssen, Lilly, Novartis, Takeda, TREG, Pfizer, and UCB; and received grants and/or research support from AbbVie (to University of Pennsylvania), Amgen (to Forward), BMS (to Forward), Forward/National Databank for Rheumatic Diseases, Janssen (to University of Pennsylvania), NIH/NIAMS, Novartis (to University of Pennsylvania), and Pfizer (to University of Pennsylvania).
Ethical Approval
This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to the PPD™ clinical research business of Thermo Fisher Scientific (Waltham, MA, USA) before the site’s participation and initiation of any study procedures. All patients enrolled in the PPD™ CorEvitas™ PsA/SpA Registry were required to provide written informed consent and authorization before participating in the study.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Verfasst von
Philip Mease
Xiaolan Ye
Christopher D. Saffore
Bhumik Parikh
Sandra Ciecinski
Taylor Blachley
Melissa Eliot
Nicole Middaugh
Alexis Ogdie
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65–70.PubMedCrossRef
2.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–68.PubMedPubMedCentralCrossRef
3.
Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511–21.PubMedCrossRef
4.
López-Medina C, Ramiro S, van der Heijde D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108.PubMedPubMedCentralCrossRef
5.
Frede N, Hiestand S, Schauer F, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther. 2023;10(6):1655–68.PubMedPubMedCentralCrossRef
6.
Coates LC, Orbai AM, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.PubMedPubMedCentralCrossRef
7.
Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020. https://doi.org/10.1136/rmdopen-2020-001223.CrossRefPubMedPubMedCentral
8.
Wervers K, Luime JJ, Tchetverikov I, et al. Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J Rheumatol. 2018;45(11):1526–31.PubMedCrossRef
9.
Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res Hoboken. 2017;69(11):1692–9.PubMedCrossRef
10.
Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91–102.PubMedPubMedCentralCrossRef
Garrido-Cumbrera M, Bundy C, Navarro-Compán V, et al. Patient-reported impact of axial spondyloarthritis on working life: results from the European map of axial spondyloarthritis survey. Arthritis Care Res Hoboken. 2021;73(12):1826–33.PubMedPubMedCentralCrossRef
13.
Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556–62.PubMedCrossRef
14.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.PubMedCrossRef
15.
van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 2018;4(1):e000582.PubMedPubMedCentralCrossRef
16.
Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689–94.PubMedCrossRef
17.
Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68(5):702–9.PubMedCrossRef
18.
Song IH, Hermann KG, Haibel H, et al. Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41(10):2034–40.PubMedCrossRef
19.
Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39–47.PubMedCrossRef
20.
Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815–22.PubMedCrossRef
21.
Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706–19.PubMedCrossRef
22.
Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79.PubMedPubMedCentralCrossRef
23.
Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.PubMedCrossRef
24.
Bautista-Molano W, Fernández-Ávila DG, Brance ML, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023;19(11):724–37.PubMedCrossRef
25.
Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613.PubMedPubMedCentralCrossRef
26.
Smolen JS, Siebert S, Korotaeva TV, et al. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419–28.PubMedCrossRef
27.
Ørnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78(11):1536–44.PubMedCrossRef
28.
Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48–53.PubMedCrossRef
29.
Coates LC, Gottlieb AB, Merola JF, et al. Comparison of different remission and low disease definitions in psoriatic arthritis and evaluation of their prognostic value. J Rheumatol. 2019;46(2):160–5.PubMedCrossRef
30.
Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811–8.PubMedCrossRef
31.
Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436–48.PubMedCrossRef
32.
Baraliakos X, Gladman DD, Chakravarty SD, et al. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatol Adv Pract. 2024;8(2):rkae058.PubMedPubMedCentralCrossRef
33.
Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.PubMed
34.
Chen YH, Huang WN, Chen YM, et al. The BASDAI cut-off for disease activity corresponding to the ASDAS scores in a Taiwanese cohort of ankylosing spondylitis. Front Med (Lausanne). 2022;9:856654.PubMedCrossRef
35.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.PubMedCrossRef
36.
Machado PM, Landewé R, Heijde DV. Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539–40.PubMedCrossRef
37.
Mease P, Walsh JA, Baraliakos X, et al. Translating improvements with ixekizumab in clinical trial outcomes into clinical practice: ASAS40, pain, fatigue, and sleep in ankylosing spondylitis. Rheumatol Ther. 2019;6(3):435–50.PubMedPubMedCentralCrossRef
38.
Kiltz U, van der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77(9):1311–7.PubMedCrossRef
39.
Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281–5.PubMed
40.
Navarro-Compán V, Ramiro S, Deodhar A, et al. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024. https://doi.org/10.1136/rmdopen-2023-004040.CrossRefPubMedPubMedCentral
41.
Gossec L, Humphries B, Rutherford M, et al. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis. Arthritis Res Ther. 2024;26(1):50.PubMedPubMedCentralCrossRef
42.
Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm. 2019;25(1):122–32.PubMed
43.
Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology (Oxford). 2019;58(1):144–8.PubMedCrossRef
44.
Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–32.PubMedCrossRef
45.
Bhagavathula AS, Bentley BL, Woolf B, Dissanayaka TD, Rahmani J. Increased risk of stroke among patients with ankylosing spondylitis: a systematic review and meta-analysis. Reumatol Clin. 2023;19(3):136–42.PubMedCrossRef
46.
Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife ankylosing spondylitis increases the risk of cardiovascular diseases in males 5 years later: a national population-based study. Medicine (Baltimore). 2016;95(18):e3596.PubMedCrossRef
47.
Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017;76(2):364–70.PubMedCrossRef
48.
Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63(11):3294–304.PubMedCrossRef
49.
Bergman MJ, Zueger P, Patel J, et al. Clinical and economic benefit of achieving disease control in psoriatic arthritis and ankylosing spondylitis: a retrospective analysis from the OM1 registry. Rheumatol Ther. 2023;10(1):187–99.PubMed
50.
Allenzara A, Bush K, Husni ME, et al. Diverse treatment goals in psoriatic arthritis: insights from participants in the PARC cohort. Arthritis Care Res (Hoboken). 2025. https://doi.org/10.1002/acr.25527.CrossRefPubMed
51.
Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol. 2016;43(9):1749–54.PubMedCrossRef
52.
Elsawy NA, Helal AH, Abd ElHamid HA, Abdel-Fattah YH. Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. Int J Rheum Dis. 2021;24(2):189–96.PubMedCrossRef
Ob und wie stark können Infektionen mit dem Respiratorischen Synzytial-Virus kardiorespiratorische Probleme auch in der postakuten Phase verursachen? Eine Studie hat das untersucht.
Eine opportunistische Eileiterentfernung reduziert das Risiko für tubo-ovarielle Karzinome um 40 bis 80% – ohne kurzfristige Nachteile für die Ovarialfunktion. Die Europäische Gynäkologievereinigung rät Frauen ohne Kinderwunsch daher, solche Eingriffe zu nutzen.
Haben Menschen mit einer chronischen Niereninsuffizienz nachts systolische Blutdruckwerte über 110 mmHg, scheint dies die Nierenfunktion weiter zu verschlechtern. Ab 65 Jahren ist es nach Daten aus China aber genau umgekehrt.
Die Behandlung eines Typ-2-Diabetes mit oralem Semaglutid scheint sich auch auf eine bestehende Herzinsuffizienz günstig auszuwirken. Laut einer Sekundäranalyse der SOUL-Studie profitieren vor allem Patienten und Patientinnen mit erhaltener Auswurffraktion.
